Contact Activation of Coagulation in Newly Inserted Central Venous Catheters

Launched by THOMAS KANDER · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of different types of central venous catheters (CVCs) on the body's blood clotting system. A CVC is a small plastic tube inserted into a large vein, usually in the neck or chest, that helps deliver medications and fluids and allows for blood sample collections. While CVCs are very useful, they can sometimes cause blood clots, which can lead to serious health issues. The goal of this study is to compare four commonly used CVCs to understand how each one affects blood clotting after they are inserted.

To be eligible for this trial, participants must be at least 18 years old and need a CVC for medical reasons. They should not be using blood-thinning medications, except for specific low-dose options. Participants will be randomly assigned to one of the four catheter types, and researchers will take two blood samples from the new catheter to see how it interacts with the blood. This study aims to gather important information that could help improve safety measures for patients using CVCs and reduce the risk of blood clots.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Participants must meet all of the following criteria to be included in the study:
• • Clinical indication for the placement of a two-lumen central venous catheter (length 150-160 mm).
• • Age ≥18 years. Signed informed consent.
• No current use of anticoagulants or platelet inhibitors, except:
• • Prophylactic low molecular weight heparin (LMWH),
• • Double prophylactic dose of LMWH,
• • Acetylsalicylic acid (ASA).
• • Exclusion Criteria
• Participants meeting any of the following criteria will be excluded:
• • Prothrombin complex (pK/INR) outside the normal range (0.9-1.2), if already available.
• • Platelet count \<140 × 10⁹/L, if already available.
• • Haemoglobin \< 80 g/L, if already available.
• * Known coagulopathic conditions, including but not limited to:
• • Activated protein C (APC) resistance,
• • Hemophilia A or B,
• • Vitamin K deficiency,
• • Disseminated intravascular coagulation (DIC),
• • Antiphospholipid syndrome,
• • von Willebrand disease, Other known congenital or acquired bleeding disorders.